環保專案成果報告查詢系統

專案計畫編號	EPA-98-E3S4-02-02
經費年度	098
計畫經費	1,660 千元
專案開始日期	2009/01/22
專案結束日期	2009/12/31
專案主持人	林郁真
主辦單位	環檢所
承辦人	潘復華
執行單位	國立台灣大學嚴慶齡工業發展基金會合設工業研究中心
專案分類	環境監測及檢測
中文關鍵字	藥物和個人保健用品，固相萃取法，液相層析串聯式質譜儀
英文關鍵字	Parmaceuticals and personal care products (PPCPs), Solid-phase extraction, LC/MS/MS
協同主持人	林正芳
共同主持人
計畫聯絡人	余宗賢
計畫聯絡電話	02-23628136#
計畫聯絡信箱	d95541004@ntu.edu.tw

中文摘要	藥物和個人保健用品(pharmaceuticals and personal care products, PPCPs)與人類之日常生活密切相關，但由於大量的使用及任意排放與丟棄，導致PPCPs普遍存在於生活廢水、廢水處理廠排放水和地表水等環境中，因此將可能進一步對環境生態系統造成衝擊。然而，PPCPs在水體環境當中相當微量(ng/L-µg/L)，因此建立精確、準確且具一致性的標準檢測方法是迫切且必要的，以便建立國內未來對於PPCPs的監測與控管機制。本工作團隊已於去年度將97-99年度水中醫藥類化學物質之檢測分析方法建立作整體規劃，並依照物化特性及文獻資料將化合物分類成三個族群，以達到較佳的回收率及更低的偵測極限，並成功建立水中26種抗生素化合物之液相層析串聯式質譜儀(LC/MS/MS)分析方法。本期末報告延續去年成果，蒐集彙整抗生素、β受體阻滯劑及β促效藥等醫藥類化學物質在水體環境中之分佈情形、生物毒性、及其可能對環境造成之衝擊等文獻資料。另調查統計國內中央健康保險局其β受體阻滯劑及β促效藥之使用量。於檢測技術建立方面，本工作團隊針對β受體阻滯劑及β促效藥(含propranolol、atenolol、metoprolol、acebutolol、tulobuterol、salbutamol、clenbuterol及ractopamine等8種)進行LC/MS/MS分析方法建立，包含固相萃取方法、LC分析條件、MRM離子對選定及其質譜參數、檢測方法確效(檢量線配製、回收率測試、基質測試、方法偵測極限等)。回收率(濃度為50 ng/L)結果顯示，去離子水及空白水樣中β受體阻滯劑及β促效藥的回收率分別介於83.2~107.2%及84.0~107.3%之間，除tulobuterol為33.8%及63.3%以外；方法偵測極限(MDL)測試結果介於0.4-1.2 ng/L。本工作團隊另運用本年度及去年度之分析檢測方法，檢測調查南部醫療院所放流水及河川水體樣品中26種抗生素、4種β受體阻滯劑及4種β促效藥等醫藥類化合物之含量。醫院放流水及河川水體之檢測結果，濃度範圍與國內外文獻相同，均介於ng/L-μg/L範圍。另就檢出頻率來看，以propranolol、acebutolol、ractopamine、sulfadimethoxine、sulfadiazine、sulfamethoxazole、sulfamethazine及lincomycin等醫藥類化合物之檢出頻率較高(檢出頻率>71%，總檢測樣品數為24件)。
中文關鍵字	藥物和個人保健用品，固相萃取法，液相層析串聯式質譜儀

中文摘要

藥物和個人保健用品(pharmaceuticals and personal care products, PPCPs)與人類之日常生活密切相關，但由於大量的使用及任意排放與丟棄，導致PPCPs普遍存在於生活廢水、廢水處理廠排放水和地表水等環境中，因此將可能進一步對環境生態系統造成衝擊。然而，PPCPs在水體環境當中相當微量(ng/L-µg/L)，因此建立精確、準確且具一致性的標準檢測方法是迫切且必要的，以便建立國內未來對於PPCPs的監測與控管機制。本工作團隊已於去年度將97-99年度水中醫藥類化學物質之檢測分析方法建立作整體規劃，並依照物化特性及文獻資料將化合物分類成三個族群，以達到較佳的回收率及更低的偵測極限，並成功建立水中26種抗生素化合物之液相層析串聯式質譜儀(LC/MS/MS)分析方法。本期末報告延續去年成果，蒐集彙整抗生素、β受體阻滯劑及β促效藥等醫藥類化學物質在水體環境中之分佈情形、生物毒性、及其可能對環境造成之衝擊等文獻資料。另調查統計國內中央健康保險局其β受體阻滯劑及β促效藥之使用量。於檢測技術建立方面，本工作團隊針對β受體阻滯劑及β促效藥(含propranolol、atenolol、metoprolol、acebutolol、tulobuterol、salbutamol、clenbuterol及ractopamine等8種)進行LC/MS/MS分析方法建立，包含固相萃取方法、LC分析條件、MRM離子對選定及其質譜參數、檢測方法確效(檢量線配製、回收率測試、基質測試、方法偵測極限等)。回收率(濃度為50 ng/L)結果顯示，去離子水及空白水樣中β受體阻滯劑及β促效藥的回收率分別介於83.2~107.2%及84.0~107.3%之間，除tulobuterol為33.8%及63.3%以外；方法偵測極限(MDL)測試結果介於0.4-1.2 ng/L。本工作團隊另運用本年度及去年度之分析檢測方法，檢測調查南部醫療院所放流水及河川水體樣品中26種抗生素、4種β受體阻滯劑及4種β促效藥等醫藥類化合物之含量。醫院放流水及河川水體之檢測結果，濃度範圍與國內外文獻相同，均介於ng/L-μg/L範圍。另就檢出頻率來看，以propranolol、acebutolol、ractopamine、sulfadimethoxine、sulfadiazine、sulfamethoxazole、sulfamethazine及lincomycin等醫藥類化合物之檢出頻率較高(檢出頻率>71%，總檢測樣品數為24件)。

中文關鍵字

藥物和個人保健用品，固相萃取法，液相層析串聯式質譜儀

類型	檔名	檔案大小	說明	最新版公開日期
期末報告	EPA-98-E3S4-02-02.pdf	4MB		2010/3/1 上午 12:00:00

摘要	The occurrence of emerging contaminants in aquatic environments has been an increasing concern among researchers, policy makers and industry personnel in many European countries and the U.S. Emerging contaminants are a group of non-regulated contaminants that still require U.S. EPA evaluations. They include a variety of compounds such as pharmaceuticals and personal care products (PPCPs), hormones and surfactants, etc. Among the variety of pharmaceuticals, antibiotics are receiving increasing attention due to their extensive use in treating diseases, protecting animals’ health and as husbandry promoters. In aquatic environments, they have the ability to alter microbial community structure and to promote the development of antibiotic-resistant human pathogens. This final report has compiled the following specific information on PPCPs: (1) environmental occurrence, (2) toxicity/estrogenicity, (3) environmental risk assessment, (4) drug usage (including amount imported and used), (5) analytical method development grouping for coming projects. In addition, this report includes our analytical results on 4 selected β-blockers and 4 selected β-agonists, including LC and mass spec optimizing conditions and QA/QC (recovery test, matrix effect study, precision and accuracy, and method detection limit). The target compounds are propranolol, atenolol, metoprolol, acebutolol, tulobuterol, salbutamol, clenbuterol and ractopamine. For recovery, DI water and real water were used as blanks, the recoveries range from 83.2-107.2% and 84.0-107.3%, respectively, except that tulobuterol are 33.8% and 63.3% for. The method detection limits (MDL) all are 1.0 ng/L. Three hospital effluents and four rivers were examined using the established analytical methods including this year and last year. Twenty-six antibiotics, 4 β-blockers and 4 β-agonists were detected in sample collected from three hospitals and four rivers. Based on analyzed data, concentrations of pharmaceuticals found were comparable to those detected around the world and were range from ng/L - μg/L. Atenolol, lincomycin, sulfadiazine, sulfamethoxazole, sulfamethazine and sulfadimethoxine were detected most frequently in all taken samples (frequency of detection >71%).
英文關鍵字	Parmaceuticals and personal care products (PPCPs), Solid-phase extraction, LC/MS/MS

摘要

The occurrence of emerging contaminants in aquatic environments has been an increasing concern among researchers, policy makers and industry personnel in many European countries and the U.S. Emerging contaminants are a group of non-regulated contaminants that still require U.S. EPA evaluations. They include a variety of compounds such as pharmaceuticals and personal care products (PPCPs), hormones and surfactants, etc. Among the variety of pharmaceuticals, antibiotics are receiving increasing attention due to their extensive use in treating diseases, protecting animals’ health and as husbandry promoters. In aquatic environments, they have the ability to alter microbial community structure and to promote the development of antibiotic-resistant human pathogens. This final report has compiled the following specific information on PPCPs: (1) environmental occurrence, (2) toxicity/estrogenicity, (3) environmental risk assessment, (4) drug usage (including amount imported and used), (5) analytical method development grouping for coming projects. In addition, this report includes our analytical results on 4 selected β-blockers and 4 selected β-agonists, including LC and mass spec optimizing conditions and QA/QC (recovery test, matrix effect study, precision and accuracy, and method detection limit). The target compounds are propranolol, atenolol, metoprolol, acebutolol, tulobuterol, salbutamol, clenbuterol and ractopamine. For recovery, DI water and real water were used as blanks, the recoveries range from 83.2-107.2% and 84.0-107.3%, respectively, except that tulobuterol are 33.8% and 63.3% for. The method detection limits (MDL) all are 1.0 ng/L. Three hospital effluents and four rivers were examined using the established analytical methods including this year and last year. Twenty-six antibiotics, 4 β-blockers and 4 β-agonists were detected in sample collected from three hospitals and four rivers. Based on analyzed data, concentrations of pharmaceuticals found were comparable to those detected around the world and were range from ng/L - μg/L. Atenolol, lincomycin, sulfadiazine, sulfamethoxazole, sulfamethazine and sulfadimethoxine were detected most frequently in all taken samples (frequency of detection >71%).

英文關鍵字

Parmaceuticals and personal care products (PPCPs), Solid-phase extraction, LC/MS/MS